4/15
06:26 am
crdl
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise [Yahoo! Finance]
Low
Report
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise [Yahoo! Finance]
4/14
08:07 pm
crdl
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart [Yahoo! Finance]
Low
Report
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart [Yahoo! Finance]
4/6
11:25 am
crdl
Cardiol Therapeutics (CRDL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $8.00 price target on the stock.
Low
Report
Cardiol Therapeutics (CRDL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $8.00 price target on the stock.
4/5
01:06 am
crdl
Low
Report
3/8
08:03 pm
crdl
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference [Yahoo! Finance]
Low
Report
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference [Yahoo! Finance]
2/25
07:42 am
crdl
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/10
01:32 pm
crdl
Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
2/6
05:33 pm
crdl
Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Medium
Report
Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
2/5
06:09 am
crdl
Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.